LogicBio Therapeutics (LOGC) Among Worst Performing On the Nasdaq

LogicBio Therapeutics (LOGC) fell almost 26% for the day, which was among the worst losses on the Nasdaq.

LogicBio Therapeutics is a clinical-stage genetic medicine company working on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. LOGC is housed in the PRISM Gene Therapy Index, which also performed poorly for the day, falling 6%.

There was no news from LogicBio today that caused the decline.

As seen in their stock chart, LOGC’s share price has fallen significantly from November.

Share this article:

About the Author

LogicBio Therapeutics (LOGC) Among Worst Performing On the Nasdaq

Editor Investors Prism